Cutaneous squamous cell carcinoma manifests as a malignant growth originating from the epidermal keratinocytes and accounts for a significant clinical challenge given its propensity to evolve into aggressive and therapy-resistant disease stages. While many cSCC cases remain manageable through conventional treatments, a subset of tumors undergo a phenotypic transition that endows them with enhanced motility and invasiveness. This transition, known as epithelial-to-mesenchymal transition (EMT), marks the shift from well-differentiated, structured epithelial cells into delocalized, mesenchymal-like cells capable of systemic dissemination. The molecular events governing this transition have remained incompletely characterized until now.

The research spearheaded by Prof. Rami I. Aqeilan and colleagues reveals that WWOX, a protein previously implicated in various tumor suppressive functions, operates as a critical guardian of epidermal identity. WWOX achieves this by stabilizing p63, a master transcription factor pivotal for maintaining epithelial cell differentiation and structural integrity. Through an intricate molecular interplay, WWOX prevents the degradation of p63, thereby preserving the genetic programs essential for keratinocyte specialization and restraining cellular plasticity.

Using an integrative approach combining genetically engineered mouse models and detailed analysis of human tissue specimens, the team demonstrated that abrogation of WWOX expression precipitates a precipitous decline in p63 levels. This destabilization effectively dismantles the safeguard mechanisms that uphold cellular identity, setting the stage for EMT induction. The resulting phenotypic fluidity enables cancer cells to shed their adhesive properties, acquire migratory traits, and penetrate systemic circulation paths, ultimately facilitating metastatic colonization, particularly in vital organs like the lungs.

Further compounding the oncogenic threat, the simultaneous loss of WWOX and the well-characterized tumor suppressor p53 was shown to accelerate tumor development dramatically. Experimental models deficient in both guardians exhibited earlier tumor onset and an escalated degree of malignancy characterized by poor differentiation and heightened invasiveness compared to controls retaining functional WWOX. These findings articulate a synergistic model whereby the concurrent impairment of multiple tumor suppressive pathways drives rapid cSCC progression.

Importantly, the translational significance of this research is underscored by investigations into human clinical samples. Through tissue microarray analyses, a consistent pattern emerged demonstrating that as cSCC advances, both WWOX and p63 protein levels diminish progressively. This correlation not only reinforces the biological importance of the WWOX-p63 axis in restraining tumor aggression but also positions these proteins as valuable prognostic biomarkers. Monitoring their expression profiles could empower clinicians to predict tumor behavior more accurately and tailor therapeutic strategies accordingly.

The implications extend into therapeutic innovation, proposing the restoration or mimicking of WWOX function as a promising intervention against aggressive cSCC. Strategies aimed at bolstering WWOX expression or enhancing p63 stability could reinforce epithelial identity and prevent the EMT process, thereby curtailing metastatic spread. This novel molecular target offers an attractive avenue for drug development efforts seeking to improve outcomes for patients afflicted with advanced skin cancers.

On a molecular level, the binding interaction between WWOX and p63 appears to be essential in preserving p63’s nuclear localization and its transcriptional activity. Loss of WWOX disrupts this complex, rendering p63 vulnerable to proteasomal degradation. This mechanistic insight provides a valuable foundation for exploring small molecules or biologics that could stabilize the WWOX-p63 interaction, representing a refined, mechanism-based therapeutic modality.

The broader context of this study situates WWOX as a pivotal component of the skin’s intrinsic tumor suppressive architecture. It exemplifies the concept that cellular identity and differentiation status are not static traits but active states maintained by molecular sentinels. The failure of these sentinels unleashes a cascade of deleterious cellular reprogramming events that fuel malignancy. Such advances reveal an evolving paradigm in oncology focusing on targeting cellular plasticity as a strategy to impede cancer progression.

Prof. Aqeilan’s pioneering work not only enriches our fundamental understanding of skin cancer biology but also lays a robust framework for future clinical applications. By integrating molecular pathology, genetic modeling, and clinical specimen analyses, it bridges the gap between bench research and patient care. This multi-disciplinary approach exemplifies how deep mechanistic insights into tumor suppressor networks can translate into actionable clinical knowledge.

As cSCC incidence rises globally due to environmental and demographic factors, the urgency for novel diagnostic and therapeutic tools escalates. This study’s identification of the WWOX-p63 axis as a central regulator of tumor behavior represents a significant leap toward meeting this need. It opens exciting new directions to explore the mechanobiology of tumor differentiation states and offers a platform to design next-generation therapies aimed at reinstating the cellular programming necessary to constrain malignancy.

In conclusion, the discovery of WWOX’s critical role in maintaining epidermal identity and suppressing EMT in skin cancer illuminates a novel molecular safeguard against tumor aggressiveness and metastasis. By stabilizing p63, WWOX fortifies the cellular differentiation landscape, preventing the dangerous transformation of skin cells into invasive cancer progenitors. This foundational knowledge promises to reshape clinical approaches to cSCC, offering hope for improved prognostication, personalized treatment regimens, and ultimately better patient outcomes.

Subject of Research: Cells
Article Title: WWOX Maintains Epidermal Identity and Suppresses EMT to Prevent Aggressive Cutaneous Squamous Cell Carcinoma
News Publication Date: 15-Apr-2026
Web References: DOI: 10.1073/pnas.2534844123
References: Proceedings of the National Academy of Sciences
Image Credits: Tirza Bidnay-Mizrahi
Keywords: Skin cancer, Carcinoma, Cancer, Metastasis, Carcinogenesis

The investigation centered on the A375 melanoma cell line, where HMGB2 upregulation was observed as a direct consequence of mechanical confinement. The authors posited that force transmission through the perinuclear acetylated tubulin network could be a critical upstream event triggering nuclear HMGB2 enrichment. To dissect this hypothesis, stable A375 cell lines with CRISPR-mediated HMGB2 knockouts (HMGB2^KO) were generated, revealing that the acetylated tubulin network remained intact even when HMGB2 was absent. This pivotal observation established that the perinuclear acetylated microtubules operate upstream of HMGB2 accumulation, rather than vice versa.

Pharmacological modulation of tubulin dynamics underscored the significance of microtubule stability in HMGB2 regulation. Treatment with the HDAC6 inhibitor tubacin, known to increase tubulin acetylation, led to a dramatic enhancement in HMGB2 nuclear levels and accelerated accumulation rates in mechanically confined cells. Intriguingly, these effects were mimicked by paclitaxel (Taxol), a drug that stabilizes microtubules by binding β-tubulin without altering acetylation status. This parallel response suggested that the mechanical stabilization of MTs, rather than acetylation per se, underlies the HMGB2 upregulation observed under confinement.

To refine their understanding of the acetylated tubulin network’s role, the researchers employed nocodazole, a potent microtubule depolymerizing agent. While nocodazole typically disrupts MT arrays, the resistant perinuclear acetylated tubulin cage persisted in treated cells. Surprisingly, HMGB2 levels remained unchanged under these conditions, affirming that perinuclear acetylated microtubules are not solely responsible for HMGB2 enrichment. Additionally, knockout of ATAT1, the enzyme catalyzing tubulin acetylation, failed to impede HMGB2 accumulation, further highlighting that acetylated tubulin contributes to but is not strictly necessary for this response. These findings hint at functional redundancy or compensatory mechanisms within the cytoskeletal architecture.

Seeking other effectors interacting with HMGB2, the team conducted TurboID proximity labeling proteomics, revealing an intriguing association with nesprin 2, a known linker of nucleoskeleton and cytoskeleton (LINC) complex protein. The LINC complex integrates cytoskeletal forces with nuclear structures, functioning as a mechanical hub. The enrichment of nesprin 2 in proximity to HMGB2 suggested that this complex mediates force transmission necessary for HMGB2 regulation during confinement. Subsequent experiments showed that nesprin 2 was itself upregulated by confinement and that siRNA-mediated knockdown of SYNE2 (the nesprin 2 gene) abrogated both HMGB2 accumulation and the perinuclear tubulin network, confirming functional interdependence.

The LINC complex is integral to nuclear mechanics, particularly in tuning nuclear stiffness through connections to the nuclear lamina. Indeed, lamin A/C protein levels surged approximately threefold in response to confinement, indicative of nuclear lamina remodeling. Atomic force microscopy corroborated these findings by demonstrating heightened nuclear stiffness in confined melanoma cells. Together, these observations illustrate a coordinated cellular strategy: remodeling of both cytoskeletal and nuclear components reinforces the cell’s structural resilience to external mechanical forces.

This adaptive remodeling ultimately culminates in the upregulation of HMGB2, a DNA-binding protein implicated in chromatin organization and transcriptional regulation. The enhanced nuclear HMGB2 may drive phenotypic plasticity, facilitating melanoma cells to endure and thrive under physical constraints characteristic of the tumor microenvironment, such as dense extracellular matrices or tight tissue spaces. This mechanotransductive pathway represents a crucial nexus linking extracellular mechanical signals to nuclear gene regulatory networks.

The meticulous dissection of microtubule dynamics, acetylation states, and their interplay with LINC complex proteins unveils a nuanced understanding of how mechanical force translates into biochemical signals modulating nuclear function. The research highlights that while acetylated microtubules form a significant structural element in force transmission, their presence is neither absolutely required nor sufficient for HMGB2 upregulation, underscoring the complexity of intracellular mechanosensing networks.

Furthermore, the identification of nesprin 2 as a critical mediator bridges cytoskeleton-nucleus communication, reinforcing the concept that mechanical properties of the cell are integrated across compartments. This integration modulates not only nuclear stiffness but also chromatin dynamics, as implied by altered HMGB2 levels, ultimately affecting gene expression programs that facilitate cancer cell adaptability and survivability.

Beyond fundamental cell biology, these discoveries offer translational potential. Targeting components of the cytoskeletal network or LINC complex may disrupt the mechanical signaling pathways that foster malignant plasticity, presenting innovative therapeutic strategies. Drugs like tubacin or Taxol, already approved or under investigation, may be repurposed to modulate tumor biomechanics and nuclear responses, potentially improving treatment outcomes.

Future research avenues prompted by this study include delineating the molecular downstream targets of HMGB2 in the context of mechanical stress and defining how these transcriptional changes affect metastatic potential. Additionally, exploring the reversibility of nuclear and cytoskeletal remodeling could shed light on phenotypic plasticity’s temporal dynamics during cancer progression.

In conclusion, this multifaceted study reveals how melanoma cells sense and respond to mechanical confinement through an orchestrated restructuring of cytoskeletal elements, nuclear components, and associated proteins, culminating in phenotypic adaptation. By decoding the biomechanical signaling pathways that govern HMGB2 upregulation and nuclear stiffening, the work charts new territory at the intersection of cell mechanics, nuclear biology, and cancer phenotypic plasticity, promising to influence both basic science and clinical oncology.

Subject of Research: Mechanical regulation of cellular phenotypic plasticity in melanoma

Article Title: Mechanical confinement governs phenotypic plasticity in melanoma

Article References:
Hunter, M.V., Joshi, E., Bowker, S. et al. Mechanical confinement governs phenotypic plasticity in melanoma. Nature (2025). https://doi.org/10.1038/s41586-025-09445-6

Image Credits: AI Generated